Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Shares Outstanding (Diluted Average) (2021 - 2025)

ARS Pharmaceuticals' Shares Outstanding (Diluted Average) history spans 5 years, with the latest figure at $98.6 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) fell 3.74% year-over-year to $98.6 million; the TTM value through Dec 2025 reached $98.6 million, down 3.74%, while the annual FY2025 figure was $98.6 million, 3.74% down from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $98.6 million at ARS Pharmaceuticals, roughly flat from $98.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $102.4 million in Q4 2024 and bottomed at $28.9 million in Q4 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $95.4 million (2023), against an average of $75.6 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) dropped 12.64% in 2022 before it skyrocketed 212.56% in 2023.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $28.9 million in 2021, then soared by 38.39% to $40.0 million in 2022, then surged by 138.3% to $95.2 million in 2023, then grew by 7.54% to $102.4 million in 2024, then decreased by 3.74% to $98.6 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Shares Outstanding (Diluted Average) are $98.6 million (Q4 2025), $98.8 million (Q3 2025), and $98.4 million (Q2 2025).